SHP647 will be administered subcutaneously in a PFS 1ml

4 trials

Sponsors

Shire Human Genetic Therapies, Inc. ("Shire"), Shire Human Genetic Therapies, Inc. ("Shire")_Now Takeda

Conditions

Crohn Disease CDModerate to Severe Crohn Disease CDModerate to Severe Ulcerative Colitis or Crohn Disease UCModerate to severe Ulcerative Colitis Ulcerative Colitis

Phase 3

A study of the Efficacy and Safety of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis

Active, not recruitingLBCTR2019090238

Shire Human Genetic Therapies, Inc. ("Shire")Moderate to severe Ulcerative Colitis Ulcerative Colitis

Start: 2019-11-01Target: 12Updated: 2026-02-02

A study of the Efficacy and Safety of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 306)

Active, not recruitingLBCTR2019090248

Shire Human Genetic Therapies, Inc. ("Shire")Crohn Disease CD

Start: 2019-11-30Target: 6Updated: 2026-02-02

A study on the Efficacy and Safety of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 307)

Active, not recruitingLBCTR2019090265

Shire Human Genetic Therapies, Inc. ("Shire")Moderate to Severe Crohn Disease CD

Start: 2020-03-30Target: 4Updated: 2026-02-02

A Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis or Crohn’s Disease

Active, not recruitingLBCTR2019090245

Shire Human Genetic Therapies, Inc. ("Shire")_Now TakedaModerate to Severe Ulcerative Colitis or Crohn Disease UC

Start: 2021-05-29Target: 8Updated: 2026-02-02